Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Trial Profile

Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Ganetespib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AML-19; AML19
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 0% as per United Kingdom Clinical Research Network record.
    • 28 Jan 2016 Planned End Date changed from 1 Jan 2021 to 1 Nov 2021 as per United Kingdom Clinical Research Network record.
    • 11 Jan 2016 According to a Celator Pharmaceuticals media release, CPX-351 (VYXEOS) has been selected for participation in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top